SCHEMBL6274818

SCHEMBL6274818

CCNC(=O)CCCN1CCc2c([nH]c3ccc(OC)cc23)C12CCN(CCOc1ccccc1)C2

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CFTR P13569 4/20 0.42
ATM Q13315 1/20 0.41
MEN1 O00255 2/20 0.40
KMT2A Q03164 2/20 0.40
KDM4E B2RXH2 1/20 0.40
NPSR1 Q6W5P4 1/20 0.40
L3MBTL1 Q9Y468 1/20 0.40
TRPA1 O75762 2/20 0.40
TRPV1 Q8NER1 2/20 0.40
KDR P35968 1/20 0.40
CHRNB2 P17787 1/20 0.39
CHRNB4 P30926 1/20 0.39
CHRNA3 P32297 1/20 0.39
CHRNA7 P36544 1/20 0.39
CHRNA4 P43681 1/20 0.39
DRD2 P14416 3/20 0.38
DRD3 P35462 3/20 0.38
MAPKAPK2 P49137 2/20 0.38
MMP1 P03956 1/20 0.38
MMP9 P14780 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6275688 0.98 CFTR (0.42) CFTRATMMEN1KMT2AKDM4E
SCHEMBL6277810 0.91 CFTR (0.46) CFTRATMMEN1KMT2AKDM4E
SCHEMBL6280952 0.90 CFTR (0.45) CFTRATMMEN1KMT2AKDM4E
SCHEMBL6280825 0.89 CFTR (0.43) CFTRATMMEN1KMT2AKDM4E
SCHEMBL6275311 0.89 CFTR (0.45) CFTRATMMEN1KMT2AKDM4E
SCHEMBL6282128 0.88 CFTR (0.47) CFTRATMMEN1KMT2AKDM4E
SCHEMBL6278306 0.87 CFTR (0.42) CFTRATMMEN1KMT2AKDM4E
SCHEMBL6278814 0.87 CFTR (0.51) CFTRMEN1KMT2AKDM4ENPSR1
SCHEMBL6275313 0.87 CFTR (0.43) CFTRATMMEN1KMT2AKDM4E
SCHEMBL6274875 0.86 CFTR (0.48) CFTRMEN1KMT2AKDM4ENPSR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20050288316-A1 Beta-carbolines as growth hormone secretagogue receptor (GHSR) antagonists BIOVITRUM AB (SE) 2005-12-29 US claimed
WO-2005048916-A2 TETRAHYDROSPIRO-BETA-CARBOLINE-1,3 '-PYRROLIDINE DERIVATIVES AND THEIR USE IN GHSR-RELATED DISORDERS BIOVITRUM AB (SE) 2005-06-02 WO claimed
US-20050288316-A1 Beta-carbolines as growth hormone secretagogue receptor (GHSR) antagonists BIOVITRUM AB (SE) 2005-12-29 US disclosed
WO-2005048916-A2 TETRAHYDROSPIRO-BETA-CARBOLINE-1,3 '-PYRROLIDINE DERIVATIVES AND THEIR USE IN GHSR-RELATED DISORDERS BIOVITRUM AB (SE) 2005-06-02 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050288316-A1 Beta-carbolines as growth hormone secretagogue receptor (GHSR) antagonists GHSR, GHRHR, PRLHR CFTR 589/4885ATM 362/4885MEN1 150/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.